Curated News
By: NewsRamp Editorial Staff
August 08, 2024
Clene Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs
Discuss on Reddit
Discuss on SubstackTLDR
- Clene (NASDAQ: CLNN) released Q2 2024 financial results and provided updates on CNM-Au8(R) programs for the treatment of ALS and Rett Syndrome.
- CNM-Au8(R) is an investigational therapy targeting mitochondrial function and the NAD pathway to improve neuronal function for neurodegenerative diseases.
- Clene's focus on developing treatments for ALS and MS has the potential to improve the lives of patients and their families, offering hope for the future.
- CNM-Au8(R) is a first-in-class therapy that targets mitochondrial health and oxidative stress, showing promise for the treatment of neurodegenerative diseases.
Impact - Why it Matters
This news matters because it provides insight into the progress of a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. The updates on CNM-Au8(R) programs for ALS and Rett Syndrome offer hope for patients and their families, with the potential for a new drug application submission later this year.
Summary
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. have released their Q2 2024 financial results, along with updates on their CNM-Au8(R) programs for treating ALS and Rett Syndrome. The company is optimistic about the potential submission of a new drug application later this year, with a focus on helping patients for whom time is critical.
Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, with operations in Utah and Maryland. For more information, visit www.Clene.com.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs
